Skip to main content

Table 8 Patients TMB10 + and b) TMMQ1 + according to mutational status

From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

a)
  TMB10 - TMB10 + Total no. patients
DWT 87 43 130
RB1 only 7 3 10
TP53 only 55 46 101
RB1 & TP53 14 19 33
Chi2, p = 0.037    
b)    
  TMMQ1 + TMMQ1 - Total no. patients
DWT 29 101 130
RB1 only 4 6 10
TP53 only 27 74 101
RB1 & TP53 15 18 33
Chi2, p = 0.048